Journal of Clinical Oncology, Vol 2, 16-20, Copyright © 1984 by American Society of Clinical Oncology
Resistance to methotrexate due to gene amplification in a patient with acute leukemia
MD Carman, JH Schornagel, RS Rivest, S Srimatkandada, CS Portlock, T Duffy and JR Bertino
A patient is described with acute myelocytic leukemia refractory to
conventional therapy, who also became highly resistant to methotrexate
(MTX) after repeated courses of this drug. Leukemia cells from this patient
were found to contain an elevated level of dihydrofolate reductase (DHFR)
activity, with no change in the affinity of the enzyme for MTX. A sensitive
"dot blot" assay revealed a fourfold increase in the gene copy number of
DHFR. Southern blot analysis with a human DHFR cDNA probe confirmed this
increase in the gene copy number, and demonstrated a similar restriction
pattern with Eco R1, Hind III, and Pst 1 as seen with a highly amplified
human leukemia cell line, K562. Additional DHFR fragments were detected,
not seen in the K562 blot, suggesting the presence of pseudogenes, or a
result of gene rearrangements occurring as part of the amplification
process. Resistance to MTX in this patient was therefore ascribed to gene
amplification and overproduction of DHFR.